The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase
S. Roumiantsev et al., The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase, BLOOD, 97(1), 2001, pp. 4-13
The effect of mutations in the Src homology 2 (SH2) domain of the BCR/ABL o
ncogene on leukemogenesis was tested in a quantitative murine bone marrow t
ransduction/transplantation assay that accurately models human Philadelphia
-positive B-lymphoid leukemia and chronic myeloid leukemia (CML), The SH2 d
omain was not required for induction of B-lymphoid leukemia in mice by BCR/
ABL, Under conditions where the p190 end p210 forms of BCR/ABL induce fatal
CML-like myeloproliferative disease within 4 weeks, p210 SH2 mutants induc
ed CML-like disease in some mice only after a significant delay, with other
recipients succumbing to B-lymphoid leukemia instead. In contrast, p190 BC
R/ABL SH2 point and deletion mutants rapidly induced CML-like disease, Thes
e results provide the first direct evidence of significant differences in c
ell signaling by the Bcr/Abl tyrosine kinase between these distinct leukemi
as, Contrary to previous observations, high levels of phosphatidylinositol
3-kinase (PI 3-kinase) activity in primary malignant lymphoblasts end myelo
id cells from recipients of marrow transduced with the BCR/ABL SH2 mutants
were found, Hence, the decreased induction of CML-like disease by the p210
BCR/ABL SH2 mutants is not due to impaired activation of PI 3-kinase. (C) 2
001 by The American Society of Hematology.